CTRI/2023/09/057448已完成4 期
To study the effectiveness of tofacitinib as a first line therapy for treatment of moderate to severe ulcerative colitis and compare it with prednisolone.
Shankar Roy0 个研究点目标入组 94 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 94
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •diagnosed cases of ulcerative colitis
排除标准
- •ulcerative proctitis, severe commorbidity, c. difficile infection, toxic mega colon, any coagulopathy or hypercoaguable condition, thrombosis, pregnancy
研究者
相似试验
尚未招募
4 期
sefulness of tofacitinib in atopic dermatitisCTRI/2024/08/072026AIIMS Bhubaneswar
招募中
1 期
Effects of Tofacitinib on Ulcerative Colitis patientslcerative Colitis.Ulcerative colitisIRCT20181217042020N2Digestive Disease Research Institute of Tehran University of Medical Sciences40
已完成
1 期
Tofacitinib therapy in Ulcerative Colitis patientsUlcerative colitislcerative Colitis.IRCT20181217042020N1Digestive Disease Research Institute of Tehran University of Medical Sciences50
尚未招募
Unknown
A comparison of efficacy and safety of oral tofacitinib vs methotrexate in management of moderate to severe chronic plaque psoriasisCTRI/2023/06/053443one
招募中
2 期
Effect of tofacitinib in COVID-19virus identifiedCondition 1: COVID-19. Condition 2: COVID-19.virus not identifiedClinically-epidemiologically diagnosed COVID-19Probable COVID-19Suspected COVID-19U07.1U07.2IRCT20200329046892N2Rasht University of Medical Sciences60